A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Inclusion Criteria: * Chinese native * Aged 18 or over * A clinical diagnosis of stable plaque psoriasis for at least 6 months * Stable plaque psoriasis on the trunk and/or limbs (excluding psoriasis on the face, scalp, genitals, and skin folds) involving 2-30% of the body surface at Day 1 (Visit 2) of the trial. * Having a Physician Global Assessment of at least 'mild' at Day 1 (Visit 2) * An mPASI score of at least 2 on the trunk and/or limbs at Day 1 (Visit 2) * Women of childbearing potential must use an adequate form of birth control throughout the trial and for at least 8 weeks after last administration of IMP * Male subjects with a female partner of childbearing potential must use adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) * Having a signed and dated informed consent. Exclusion Criteria: * Systemic use of biological treatments with a potential effect on psoriasis vulgaris within the specified time periods prior to treatment assignment (depending on treatment) * Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris within 4 weeks prior to treatment assignment * Psoralen combined with ultraviolet A therapy (PUVA) within 4 weeks prior to treatment assignment * Systemic treatment with Apremilast within 4 weeks prior to treatment assignment * Ultraviolet B (UVB) therapy within 2 weeks prior to treatment assignment * Topical treatment of psoria…